RU2018102808A - Полный синтез шишиджимицина а и его аналогов - Google Patents

Полный синтез шишиджимицина а и его аналогов Download PDF

Info

Publication number
RU2018102808A
RU2018102808A RU2018102808A RU2018102808A RU2018102808A RU 2018102808 A RU2018102808 A RU 2018102808A RU 2018102808 A RU2018102808 A RU 2018102808A RU 2018102808 A RU2018102808 A RU 2018102808A RU 2018102808 A RU2018102808 A RU 2018102808A
Authority
RU
Russia
Prior art keywords
substituted
alkoxy
alkyl
hydrogen
alkanediyl
Prior art date
Application number
RU2018102808A
Other languages
English (en)
Russian (ru)
Other versions
RU2018102808A3 (enExample
Inventor
Кириакос С. Николаоу
Жотань ЛИ
Чжаоюн ЛУ
Те-лк СОХН
Джеймс ВУДС
Эмманоуил Н. ПИЦИНОС
Original Assignee
Уильям Марш Райс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уильям Марш Райс Юниверсити filed Critical Уильям Марш Райс Юниверсити
Publication of RU2018102808A publication Critical patent/RU2018102808A/ru
Publication of RU2018102808A3 publication Critical patent/RU2018102808A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2018102808A 2015-06-29 2016-06-29 Полный синтез шишиджимицина а и его аналогов RU2018102808A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186191P 2015-06-29 2015-06-29
US62/186,191 2015-06-29
PCT/US2016/040047 WO2017004172A1 (en) 2015-06-29 2016-06-29 Total synthesis of shishijimicin a and analogs thereof

Publications (2)

Publication Number Publication Date
RU2018102808A true RU2018102808A (ru) 2019-07-30
RU2018102808A3 RU2018102808A3 (enExample) 2020-04-30

Family

ID=57609044

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018102808A RU2018102808A (ru) 2015-06-29 2016-06-29 Полный синтез шишиджимицина а и его аналогов

Country Status (19)

Country Link
US (1) US10590158B2 (enExample)
EP (1) EP3313389A1 (enExample)
JP (1) JP2018525346A (enExample)
KR (1) KR20180053294A (enExample)
CN (1) CN108348489A (enExample)
AR (1) AR105193A1 (enExample)
AU (1) AU2016286071A1 (enExample)
BR (1) BR112017028557A2 (enExample)
CA (1) CA2990206A1 (enExample)
CL (1) CL2017003500A1 (enExample)
HK (1) HK1254923A1 (enExample)
IL (1) IL256345A (enExample)
MA (1) MA42273A (enExample)
MX (1) MX2017016885A (enExample)
PE (1) PE20180658A1 (enExample)
PH (1) PH12018500014A1 (enExample)
RU (1) RU2018102808A (enExample)
TW (1) TW201713634A (enExample)
WO (1) WO2017004172A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110357785B (zh) * 2019-07-26 2020-03-24 东莞市领创环保材料科技有限公司 一种氰酸酯树脂增塑剂的制备方法
CN115197188B (zh) * 2021-04-12 2023-12-26 南开大学 一类具有五环骨架的倍半萜氢醌化合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264586A (en) * 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5261586A (en) * 1992-03-26 1993-11-16 Chen Jen Fu Yarn feeding device with a guiding flange
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
JP2003238584A (ja) * 2002-02-08 2003-08-27 Yamanouchi Pharmaceut Co Ltd 新規エンジイン化合物
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US10131682B2 (en) * 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules

Also Published As

Publication number Publication date
PH12018500014A1 (en) 2018-07-09
WO2017004172A1 (en) 2017-01-05
IL256345A (en) 2018-02-28
MA42273A (fr) 2018-05-02
US10590158B2 (en) 2020-03-17
CL2017003500A1 (es) 2018-04-27
AU2016286071A8 (en) 2019-08-08
AU2016286071A1 (en) 2018-02-01
CN108348489A (zh) 2018-07-31
BR112017028557A2 (pt) 2018-09-04
AR105193A1 (es) 2017-09-13
MX2017016885A (es) 2018-09-06
EP3313389A1 (en) 2018-05-02
US20180327439A1 (en) 2018-11-15
PE20180658A1 (es) 2018-04-17
JP2018525346A (ja) 2018-09-06
HK1254923A1 (zh) 2019-08-02
CA2990206A1 (en) 2017-01-05
TW201713634A (zh) 2017-04-16
WO2017004172A8 (en) 2018-01-11
KR20180053294A (ko) 2018-05-21
RU2018102808A3 (enExample) 2020-04-30

Similar Documents

Publication Publication Date Title
CA2750413A1 (en) Hydroxamic acid derivatives
ES2582471T3 (es) Inhibidores polibásicos de la bomba de flujo de salida bacteriana que contienen boro y usos terapéuticos de los mismos
JP2018504379A5 (enExample)
RU2012124056A (ru) Спирооксиндольные антагонисты mdm2
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
RU2014145121A (ru) Пиримидиновые соединения для лечения злокачественной опухоли
JP2019513734A5 (enExample)
JP2012515776A5 (enExample)
JP2020502049A5 (enExample)
JP2019512478A5 (enExample)
JP2018504378A5 (enExample)
CA2653941A1 (en) Substituted amino purine derivatives and uses thereof
RU2018102365A (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
JP2018507197A5 (enExample)
RU2013153388A (ru) Способы применения активаторов пируваткиназы
RU2015119557A (ru) Конъюгаты лекарственное вещество-белок
AR066348A1 (es) Inhibidores de las iap
JP2011517453A5 (enExample)
RU2010115886A (ru) Cd19-связывающие средства и их применение
EA201070437A3 (ru) Способ получения 2'-дезокси -5-азацитидина (децитабина)
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
JP2013538213A5 (enExample)
JP2019519593A5 (enExample)
JP2018530582A5 (enExample)
RU2011129652A (ru) Способ получения активированных сложных эфиров

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200924